Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ABBV-706 + atezolizumab
- Development stage
- Unknown
- Lead developer
- AbbVie
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
ABBV-706 + atezolizumab is an investigational combination therapy consisting of **ABBV-706**, an antibody-drug conjugate targeting seizure-related homolog protein 6 (SEZ6), and **atezolizumab (Tecentriq)**, a monoclonal antibody immune checkpoint inhibitor against programmed death-ligand 1 (PD-L1)[2][3]. ABBV-706 delivers a topoisomerase-1 inhibitor payload to SEZ6-expressing cancer cells, inducing cytotoxicity primarily in small cell lung cancer (SCLC) and other neuroendocrine tumors. Atezolizumab blocks PD-L1 to restore and enhance T-cell mediated antitumor immune responses. This combination is currently being evaluated as first-line therapy in extensive-stage SCLC and may have application in other advanced solid tumors[2][3].
- Other names
- ABBV-706ABBV706ABBV 706atezolizumabTecentriq
02
Targets
TOP1 (DNA Topoisomerase I)SEZ6CD274 (Programmed cell death protein 1 ligand 1)
Beyond the preview
Go deeper on ABBV-706 + atezolizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ABBV-706 + atezolizumab.